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 Elevated circulating levels of the gut microbiota-derived metabolite, trimethylamine N-
oxide (TMAO), are associated with adverse outcomes in heart failure (HF) (1-4). However, 
there are apparent discrepancies in the reported relationship between TMAO levels and 
outcomes. Independent reports from a British acute HF cohort (1) and from a Norwegian 
chronic HF cohort (2) showed attenuation of association of TMAO levels with outcomes after 
adjustment for main confounders, namely renal function. In contrast, in a German chronic HF 
population, TMAO levels were reported to be associated with mortality and had a better 
predictive value than N-terminal pro-B-type natriuretic peptide (NT-proBNP) even after 
adjustment for glomerular filtration rate (eGFR) (3). We therefore wondered whether 
geographical location might account for this apparent difference (5) and investigated this 
hypothesis using the BIOSTAT-CHF cohort (4, 6, 7), a multinational study done across 11 
countries in Europe in which we recently reported the association between TMAO levels and 
outcomes (4). 
 A diet-based categorization by country of enrolment was performed using the European 
Nutrition and Health Report classification (8) into the Northern/Western group (NW: France, 
Netherlands, Norway, Sweden, and United Kingdom), Central/Eastern group (CE: Germany, 
Poland, Serbia, and Slovenia), and Southern group (S: Greece and Italy) (Figure 1). The 
primary study endpoint was 2-year all-cause mortality. The association between TMAO and 
mortality was assessed by Cox proportional hazards analysis within each geographical group, 
adjusted for the modified BIOSTAT full risk model (Figure 1) (6) and for further specific 
TMAO confounders: eGFR, body mass index (BMI), and protein uptake (as estimated by the 
Maroni formula). The effects of geographical location on addition of TMAO or NT-proBNP 
to the BIOSTAT risk model for mortality and interaction with TMAO were investigated.  
Further, genetic effects on TMAO by the enzyme critical for conversion of TMAO from its 
precursor TMA, the flavin-containing monooxygenase isoform 3 (FMO3) gene (i.e. four 
common gene polymorphisms of the A allele of rs2266782 and rs1736557, G allele of 
rs2266780, and T allele of rs909530) (9), were investigated using linear regression under an 
additive mode of inheritance further adjusting for the first 10 genetic principle components. 
Genotyping was carried out on the Affymetrix Axiom UK Biobank array and called using 
Affymetrix Power Tools 1.16.1. A p-value of <0.05 was considered statistically significant.  
 Of 2234 patients in BIOSTAT-CHF, 952 (43%) were classified as NW, 714 (32%) as 
CE, and 568 (25%) as S. Geographical differences in demographics, comorbidities, and 
mortality were in line with previous reports on geographical characteristics of patients with HF 
(i.e. CE patients showing a younger age, a higher percentage of ischemic disease, and different 
outcomes) (5). CE patients were younger, had higher eGFR, higher estimated protein intake, 
and higher percentage of ischemic aetiology compared to NW but were similar to S patients 
(Figure 1 and Table 1). When adjusted for age, eGFR, protein intake, and BMI, TMAO levels 
in CE remained significantly lowest amongst regions (median [IQR]: 6.2 µM [4.8-6.8], 7.2 µM 
[5.4-8.9], and 6.5 µM [5.0-8.5] respectively for CE, NW and S, p for trend <0.001). 
Approximately 24% of patients (n=531) reached the primary endpoint during a median follow-
up of 21.5 [15.7-24.3] months. Mortality rate varied amongst regions [NW 26.7% (n=254), CE 
22.0% (n=157), and S 21.1% (n=120), p for trend=0.019]. In a Cox model adjusted for 
confounders including BIOSTAT risk model factors, the CE group alone showed significant 
association of higher TMAO levels with mortality (HR: 2.40 (1.33-4.32); p=0.004) (Figure 1). 
When interaction between geographical differences with TMAO or NT-proBNP levels and 
outcome was investigated, a statistically significant interaction for TMAO alone was observed 
but not for NT-proBNP (p interaction= 0.033 and 0.586 respectively). Further, NT-proBNP 
levels were significantly associated with mortality after adjustment for confounders in all 
groups. However, TMAO levels significantly improved risk prediction when added to the 
BIOSTAT risk model in CE patients alone,  as shown by changes in C-statistic (0.718 to 0.744, 
p=0.046), NRI (41.9 [21.2-62.7], p<0.001), and IDI (2.3 [0.9 – 3.7], p<0.001) (Supplementary 
table 1). In contrast, for NT-proBNP there was a statistically significant gain in C-statistic, 
NRI, and IDI in all groups, (Supplementary table 1). No associations of four previously 
identified genetic variants in the FMO3 gene with TMAO levels were observed 
(Supplementary table 2).  
 This is the first report on effects of regional differences on association between TMAO 
levels and mortality risk in HF. There are two main findings of the present analysis. First, 
TMAO levels of HF patients differed by region, even after adjustment for confounders. Second, 
there was a different association with outcome by region (i.e. mortality risk of patients with 
elevated TMAO levels was higher in CE patients than in NW and S patients). In addition to 
these main findings, in CE patients, TMAO levels were predictive of mortality on C-statistic 
analysis. Finally, a genetic interaction was not seen of known FMO3 gene variants with TMAO 
levels. Collectively, our findings demonstrate the different associations of TMAO with HF 
outcomes in a European population suggesting that geographical differences apart from 
demographic and comorbidities might represent at least one possible explanation for this (1-3). 
The BIOSTAT-CHF cohort has two features that made it an ideal cohort to investigate regional 
discrepancies. First, patients from different European regions (NW, CE and S) were well 
represented in our cohort. Second, with more than 99% of patients being Caucasian, the role 
of ethnicity and the genetic pool was mitigated as possible confounders of underlying 
geographical differences (5). There were several limitations in the present study, however. 
Although we estimated protein intake by the Maroni formula, we did not have any information 
regarding the actual dietary records, gut microbiota composition or intestinal permeability to 
confirm the impact of diet on TMAO levels.  
 In conclusion, geographical differences affect the levels and association of TMAO with 
heart failure mortality, regardless of  confounders. This finding sheds light upon possible 
effects of under-investigated factors that affect associations of TMAO and other biomarkers of 
HF with adverse outcomes.  
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Figure 1. Association between TMAO/NT-proBNP and all-cause mortality at 2 years according to geographical groups. 
Forest plot of the hazard ratio (HR) of 2-year mortality risk per log TMAO/NT-proBNP increase. Whiskers represent 95% confidence intervals (CI). 
HRs adjusted for modified BIOSTAT-CHF full risk model factors (age, log urea, haemoglobin, use of beta-blocker at baseline, log NT-proBNP, ischemic 
aetiology, chronic obstructive pulmonary disease, diastolic blood pressure, and sodium), glomerular filtration rate, body mass index, and protein uptake.
Table 1. Patient characteristics regarding geographical groups. 
 
  Northern/Western Central/Eastern Southern p for 
trend   (n=952) (n=714) (n=568) 
Demographics      
  Age 74 [64–80] † 67 [59–75] 68 [59–76] † <0.001 
  Male 627 (66%)* 548 (77%) 479 (84%) <0.001 
  Body mass index (kg/m2) 26.9 [23.7–30.9] * 27.5 [24.7–31.1] 27.5 [24.4–29.8] 0.005 
  Current smoker 122 (13%) 106 (15%) 84 (15%) 0.407 
  Ischemic aetiology 477 (51%)* 432 (62%) 305 (56%) <0.001 
  Hypertension 516 (54%)* 540 (76%) 345 (61%)* <0.001 
  Diabetes mellitus 273 (29%) 246 (35%) 211 (37%) 0.001 
  Atrial fibrillation 470 (49%) † 293 (41%) 243 (43%) 0.002 
  COPD 180 (19%) † 101 (14%) 106 (19%) 0.025 
  Previous HF hospitalisation 260 (27%)* 229 (32%) 214 (38%) <0.001 
  NYHA class (%) I/II/III/IV  2/34/51/12† 1/39/53/7 5/33/45/17† <0.001 
  LV ejection fraction (%) 30 [25–40] † 30 [25–36] 30 [25–35] <0.001 
Clinical signs      
  Pulmonary congestion 513 (57% )† 325 (46%) 311 (56%) † <0.001 
  Peripheral oedema 523 (69%) † 358 (55%) 222 (50%)* <0.001 
  Systolic blood pressure (mmHg) 120 [110–139] * 125 [110–140] 120 [110–130] * <0.001 
  Diastolic blood pressure (mmHg) 71 [63–83] * 78 [70–85] 70 [69–80] * <0.001 
  Heart rate (beat/min) 79 [68–95] † 75 [66–84] 75 [66–86] † <0.001 
Medication      
  Beta-blocker 755 (79%)* 629 (88%) 479 (84%) 0.017 
  ACE inhibitor or ARB 673 (71%)* 569 (80%) 396 (70%)* <0.001 
  MRA 379 (40%)* 475 (67%) 339 (60%) <0.001 
  Diuretics 950 (100%) 714 (100%) 568 (100%) 0.260 
Laboratory       
  Haemoglobin (g/dL) 13.0 [11.7-14.4] * 13.7 [12.3-14.7] 13.2 [11.8-14.4] * <0.001 
  Urea (mmol/L) 9.0 [6.7-13.1] 9.5 [6.9-15.0] 18.2 [12.5-26.1] <0.001 
  Sodium (mmol/L) 139 [137-141] * 140 [138-142] 139 [137-142] * <0.001 
Outcomes (2 years)      
  Mortality  254 (27%) † 157 (22%) 120 (21%) 0.019 
 
Data are expressed as median [interquartile range] for continuous variables or n (%) for categorical 
values. P values are quoted for Kruskal-Wallis tests for continuous variables and Chi-square tests for 
categorical variables. ACE=angiotensin-converting enzyme; ARB=angiotensin receptor blocker; 
COPD=chronic obstructive pulmonary disease; HF=heart failure; IDI= integrated discrimination 
improvement; LV=left ventricular; MRA=mineralocorticoid receptor antagonist; NRI= net 
reclassification improvement; NT-proBNP=N-terminal pro-B-type natriuretic peptide; NYHA=New 
York Heart Association; TMAO=trimethylamine-N-oxide;  
†Significantly higher compared to CE; *significantly lower compared to CE pairwise analyses.   
Supplementary table 1. Added value performance for TMAO or BNP over the BIOSTAT risk model according to geographical groups.  
            C-statistic 
p value NRI [% (95% CI)] p value IDI [% (95% CI)] p value 
  BIOSTAT model adding  
TMAO               
Northern/Western 0.725 0.725 0.736 4.6 (-5.7 - 1.1) 0.587 0.1 (-0.2 - 0.2) 0.632 
Central/Eastern 0.718 0.744 0.046 41.9 (21.2 - 62.7) <0.001 2.3 (0.9 - 3.7) <0.001 
Southern 0.733 0.732 0.968 0.4 (-22.9 - 23.8) 0.970 0.3 (-0.4 - 1.1) 0.344 
NT-proBNP               
Northern/Western 0.725 0.749 0.009 35.3 (18.9 - 51.6) <0.001 2.7 (1.4 - 4.0) <0.001 
Central/Eastern 0.718 0.750 0.023 41.1 (20.2 - 61.9) <0.001 4.7 (2.6 - 6.7) <0.001 
Southern 0.733 0.770 0.043  50.7 (28.1 - 73.2) <0.001 5.6 (3.0 - 8.2) <0.001 
IDI= integrated discrimination improvement; NRI= net reclassification improvement; NT-proBNP=N-terminal pro-B-type natriuretic peptide; 
TMAO=trimethylamine-N-oxide. Modified BIOSTAT risk model included age, log urea, haemoglobin, use of beta-blocker at baseline, ischemic aetiology, 
chronic obstruct pulmonary disease, diastolic blood pressure, and sodium. 
 
Supplementary table 2. Association between genetic variants of FMO3 and TMAO levels.  
SNP Position (b37) EA EAF Beta 95% CI P value 
rs2266782 171076966 A 0.399 -0.019 -0.091, 0.053 0.604 
rs1736557 171080080 A 0.072 -0.043 -0.105, 0.020 0.183 
rs909530 171083174 T 0.220 -0.008 -0.108, 0.092 0.878 
rs2266780 171083242 G 0.162 -0.009 -0.062, 0.045 0.756 
 
SNP= Single Nucleotide Polymorphism; EA= Effect allele; EAF= Effect allele frequency. Results are adjusted for sex, age, geographical location, log-
transformed protein intake, BMI, eGFR, and the first 10 genetic principle components. 
 
